Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis

Lee, Hee Jin; Kim, Joo Young; Song, In Hye; Park, In Ah; Yu, Jong Han; Gong, Gyungyub

doi:10.1159/000439535

Cited by 29 publications

(26 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We decided to examine the expression of the NY-ESO-1 gene in patients with lymphoma, as it is a CTA present in various types of cancer and is associated with clinical factors such as poor prognosis and lower survival. [18][19] We confirmed that NY-ESO-1 gene expression is associated with the advanced stage of the disease, changes in the levels of LDH and the IPI, and survival rates. In DLBCL, there are no reports of an association between the expression of this gene and clinical parameters.…”

supporting

confidence: 63%

Frequency and Clinical Association of NY-ESO-1 Gene Expression in Diffuse Large B-cell Lymphoma.

Carrilo

Peñafiel

Miranda-Peralta

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Diffuse Large B-cell Lymphoma, a heterogeneous disease, is influenced by complex network of gene interactions. In current study, we aimed to evaluate the frequency of expression and determine the expression levels of the NY-ESO-1 gene in patients with DLBCL, as well as to examine its relationship with clinical parameters and survival. Methods We analyzed NY-ESO-1 gene expression levels using real-time quantitative RT-PCR (qRT-PCR) in 112 patients with DLBCL. The associations between the expression of the NY-ESO-1 gene and the clinical variables were evaluated using the chi-square test and Fisher’s exact test. Overall survival (OS) was determined using the Kaplan-Meier method. Result The results showed that the NY-ESO-1 gene was expressed in 46.4% (52/112) of patients with DLBCL, and NY-ESO-1 gene expression was associated with clinical parameters such as LDH, clinical stage, international prognostic index (IPI) (p≤0.05). High levels of NY-ESO-1 gene expression were correlated with advanced disease stages, and the survival rates after 5.3 years of tracking were lower in the patients expressing the NY-ESO-1 gene (66.4%) than in those not expressing the gene (23.1%). Conclusion In conclusion, the expression levels of the NY-ESO-1 gene in patients with DLBCL may be of great utility for diagnosing and determining the prognosis of this disease.

show abstract

supporting

confidence: 63%

Frequency and Clinical Association of NY-ESO-1 Gene Expression in Diffuse Large B-cell Lymphoma.

Carrilo

Peñafiel

Miranda-Peralta

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…This would explain the lack of association with CD8 positive cells, unlike the situation in IDC, where CT antigen expression often correlates with CD8 TIL infiltration [15, 16]. …”

Section: Discussionmentioning

confidence: 99%

NY-ESO-1 expression in DCIS: A new predictor of good prognosis

et al. 2017

View full text Add to dashboard Cite

BackgroundAt present, it is difficult to predict which patients with ductal carcinoma-in-situ (DCIS) will subsequently develop frank invasive breast cancer (IDC). A recent survey by our group has shown that NY-ESO-1 and MAGEA are both expressed in DCIS. This study was aimed at determining whether expression of these antigens was related to the later development of IDC.Results14 of 42 (33%) of patients developed invasive breast cancer during the follow up period. Only one of those DCIS cases that relapsed was positive for NYESO-1 at diagnosis. In contrast, DCIS samples of 15 of the 28 (54%) of those patients who remained disease-free expressed NY-ESO-1. (Permutation chi square p=0.0033).MethodsWe identified 42 patients with DCIS, and followed them up for more than 10 years. NY-ESO-1 and MAGEA were demonstrated by immunostaining as were CD8+ infiltrates on all sections together with the conventional markers, ER, PR, and HER2.ConclusionsExpression of NY-ESO-1 may predict those patients who will not subsequently develop invasive breast cancer and could therefore potentially be helpful in defining prognosis in patients with DCIS.

show abstract

“…Early clinical data and assays in some respects support the rationale for further investigations of SP17 for tumour vaccines [ 157 ]. NY-ESO-1 expression is an independent good prognostic factor (p = 0.046) in TNBC and leads to a high humoural immune response associated with higher TILs [ 158 , 159 ]. Therefore, the detection of NY-ESO-1 expression in TNBC might be useful for selecting patients who may benefit from cancer vaccination therapy.…”

Section: Cancer Vaccinementioning

confidence: 99%

Immunotherapeutic interventions of Triple Negative Breast Cancer

Qiu

et al. 2018

J Transl Med

104

View full text Add to dashboard Cite

Triple Negative Breast Cancer (TNBC) is a highly heterogeneous subtype of breast cancer that lacks the expression of oestrogen receptors, progesterone receptors and human epidermal growth factor receptor 2. Although TNBC is sensitive to chemotherapy, the overall outcomes of TNBC are worse than for other breast cancers, and TNBC is still one of the most fatal diseases for women. With the discovery of antigens specifically expressed in TNBC cells and the developing technology of monoclonal antibodies, chimeric antigen receptors and cancer vaccines, immunotherapy is emerging as a novel promising option for TNBC. This review is mainly focused on the tumour microenvironment and host immunity, Triple Negative Breast Cancer and the clinical treatment of TNBC, novel therapies for cancer and immunotherapy for TNBC, and the future outlook for the treatment for TNBC and the interplay between the therapies, including immune checkpoint inhibitors, combination of immune checkpoint inhibitors with targeted treatments in TNBC, adoptive cell therapy, cancer vaccines. The review also highlights recent reports on the synergistic effects of immunotherapy and chemotherapy, antibody–drug conjugates, and exosomes, as potential multifunctional therapeutic agents in TNBC.

show abstract

Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis

Cited by 29 publications

References 39 publications

Frequency and Clinical Association of NY-ESO-1 Gene Expression in Diffuse Large B-cell Lymphoma.

Frequency and Clinical Association of NY-ESO-1 Gene Expression in Diffuse Large B-cell Lymphoma.

NY-ESO-1 expression in DCIS: A new predictor of good prognosis

Immunotherapeutic interventions of Triple Negative Breast Cancer

Contact Info

Product

Resources

About